Found 5 clinical trials
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided …
- 0 views
- 02 Aug, 2021
- 158 locations
Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury
background about neurotrophic and neuroprotective effects of this hematopoietic growth factors therapy.
- 0 views
- 26 Jan, 2021
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor graft function or delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.
- 17 views
- 07 Nov, 2020
- 1 location
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
The purpose of this study is to determine if AR-67 is effective in the treatment for patients with MDS.
- 30 views
- 08 Nov, 2020
- 1 location
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"
Bone marrow consists of a complex hematopoietic cellular component.When the blood progenitor cells differentiate to mature cells, they will exit unassisted to peripheral blood. On the other hand, the immature cells trapped by marrow-blood barrier. However, malignant transformation of the hematopoietic progenitor cells in AML and CML results in a …
- 14 views
- 07 Nov, 2020
- 1 location